Eligibility check
Answer a few questions and we compare your situation with the published access and reimbursement criteria in your country — then show you exactly which listed providers fit. It takes about two minutes, and nothing you enter is stored or sent anywhere: the check runs entirely in your browser.
Check your eligibility — in about 2 minutes
Answer a few questions and we’ll compare your situation with the published access and reimbursement criteria in your country. This is a self-assessment, not medical advice.
Informational self-assessment only. This eligibility check compares your answers with published access and reimbursement criteria. It is not a medical diagnosis, medical advice, or a treatment decision, and it cannot determine whether treatment is right or safe for you. Always consult a licensed clinician. In a crisis, contact local emergency services or a crisis line immediately.
What we check against
- GermanyPublished reimbursement practice centres on a severe, treatment-resistant depressive episode; “adequate” antidepressant treatments mean a sufficient dose taken for several weeks, and the route differs for statutory (GKV) and private (PKV) insurance.
- FrancePublished French reimbursement criteria apply to adults under 65, after at least 2 antidepressants from 2 different classes have failed to bring sufficient improvement; treatment is organised through a hospital — the standard access route in France.
- SpainPublished Spanish criteria cover adults aged 18–74, after at least 3 treatment strategies have failed, including at least one augmentation strategy (adding a second medicine to an antidepressant).
- NetherlandsDutch criteria follow the depression treatment algorithm — usually 3 or more adequate treatment steps including an augmentation step, then referral to a specialised esketamine centre (ENC-NL network).
- PolandDrug programme B.147 requires depression documented as treatment-resistant by a clinician, antidepressants failed at adequate dose and duration, and NFZ (National Health Fund) coverage.
- SwitzerlandThe Swiss limitation requires both at least 2 antidepressants and at least 1 augmentation attempt without sufficient improvement, an illness rated as severe (e.g. a CGI-S score of 5 or higher), treatment at a BAG-designated centre, and insurer pre-approval of cost coverage.
- United KingdomNICE has not recommended esketamine (Spravato®) for routine NHS use, so NHS reimbursement is generally not available; access runs mainly through private, self-pay clinics regulated by the CQC, typically £300–£800 per session.
This is an informational self-assessment, not medical advice and not a clinical screening. It only mirrors criteria that regulators, payers and clinics publish; the actual eligibility decision is always made by a treating clinician, and every provider runs its own pre-screening before treatment.
Before you speak to a clinician
If you do not have a confirmed diagnosis yet, a validated self-screener can help you describe your symptoms in the language clinicians use. A validated questionnaire is not a diagnosis, but it can help you prepare for a conversation with a clinician.
- Depression · PHQ-9Depression screening test — the 9-item PHQ-9, the same questionnaire clinicians use to grade depressive symptoms over the past two weeks (about 2 minutes).
- Anxiety · GAD-7Anxiety screening test — the 7-item GAD-7 scale, scoring anxiety severity from minimal to severe (about 1 minute).
- PTSD · PCL-5-basedPTSD screening test — mirrors the PCL-5 checklist across the four DSM-5 symptom clusters, including complex-PTSD patterns (about 3 minutes).
- Alcohol use · AUDITAlcohol use test — based on the WHO’s 10-item AUDIT, mapping drinking patterns over the past year to risk bands (about 2 minutes).